
    
      This study will be a phase II open label interventional case series. Patients with
      retinoblastoma will be randomized to receive chemotherapy with or without intravitreal
      ranibizumab at a dose of 0.5mg/0.05 ml. Patients will receive ranibizumab via a pars plana
      injection on a monthly basis for a total duration of therapy of 6 months. Patients will be
      followed for 24 months .
    
  